₹41,700 Cr
--
₹-1,502 Cr
As on 13-Aug-2024 IST
₹-24.45
•
-1.63%
₹1,502.50
₹1,510.00
₹1,520.00
₹1,461.50
12,40,620
₹722.10 - 1,520.00
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
| 73.08 | 6.99 | 44.35 | 84.44 | 37.34 | 28.24 | 8.00 |
|
BSE Healthcare
| 30.05 | 6.86 | 18.26 | 46.79 | 16.31 | 26.45 | 12.81 |
|
BSE Mid Cap
| 26.89 | -1.61 | 13.94 | 53.62 | 26.75 | 27.88 | 17.84 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
| 101.33 | -19.75 | 5.16 | 42.75 | -49.80 | 16.26 | -33.06 |
|
BSE Mid Cap
| 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 | 48.13 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Glenmark Pharmaceuticals Ltd stood at ₹ 14,359 Cr as on 31-Mar-24
The share price of Glenmark Pharmaceuticals Ltd is ₹1,478.05 (NSE) and ₹1,477.75 (BSE) as of 13-Aug-2024 IST. Glenmark Pharmaceuticals Ltd has given a return of 37.34% in the last 3 years.
Glenmark Pharmaceuticals Ltd has a market capitalisation of ₹ 41,700 Cr as on 13-Aug-2024. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Glenmark Pharmaceuticals Ltd is 5.31 times as on 13-Aug-2024, a 24% premium to its peers’ median range of 4.29 times.
Since, TTM earnings of Glenmark Pharmaceuticals Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Glenmark Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.
The promoter of Glenmark Pharmaceuticals Ltd is SALDANHA FAMILY TRUST. SALDANHA FAMILY TRUST owns 45.45 per cent of the total equity. The chairman of the company is Glenn Saldanha , and the managing director is Glenn Saldanha..
There is no promoter pledging in Glenmark Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
33,841
|
|
|
25,812
|
|
|
24,740
|
|
|
24,056
|
| Glenmark Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-29.11
|
|
Operating margin(%)
|
6.53
|
|
Net Margin(%)
|
-13.02
|
|
Dividend yield(%)
|
0.17
|
No, TTM profit after tax of Glenmark Pharmaceuticals Ltd was ₹-1,502 Cr.
₹41,700.35 Cr
₹12,178.64 Cr
₹-1,501.66 Cr
₹1,659.46 Cr
₹4,347.72 Cr
46.65%
High
₹722.10 - 1,520.00
₹1.00
28,21,88,156
NSE: GLENMARK, BSE: 532296
Mumbai, Maharashtra
www.glenmarkpharma.com
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic... formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India. Read more
Stocks 
Glenmark Pharmaceuticals Ltd.
Widely used:
